

Application for extension of patent term  
of US Patent No. 5,202,333

ATTACHMENT G

(Copy of authorization from Helsinn Healthcare SA to Roche Palo Alto LLC  
to rely upon the activities of Helsinn Healthcare SA before the US Food and Drug Administration  
in making its application for extension of patent term)



Commissioner of Food and Drugs  
US Food and Drug Administration  
5600 Fishers Lane  
Rockville MD 20857-0001

Management

Commissioner for Patents  
PO Box 1450  
Alexandria VA 22313-1450

Pazzallo, August 18, 2003

**Re: Application for Extension of Patent Term of US Patent No. 5,202,333  
"Tricyclic 5-HT<sub>3</sub> receptor antagonists"  
Roche Palo Alto LLC**


Gentlemen:

Helsinn Healthcare SA is the licensee of Roche Palo Alto LLC under US Patent No. 5,202,333 and the holder of Investigational New Drug exemption 39,797 (for palonosetron hydrochloride) and New Drug Application 21-372 (for Aloxi™ (palonosetron hydrochloride) injection).

Helsinn Healthcare SA hereby authorizes Roche Palo Alto LLC to rely upon the activities of Helsinn Healthcare SA before the US Food and Drug Administration during the regulatory review period in making its application for extension of the patent term of US Patent No. 5,202,333; and grants the Commissioner of Food and Drugs and the Commissioner for Patents the right to refer to the above IND and NDA in determining the eligibility of Roche Palo Alto LLC for such extension.

For and on behalf of

HELINN HEALTHCARE SA



Dr. Riccardo Braglia  
Managing Director



Commissioner of Food and Drugs  
US Food and Drug Administration  
5600 Fishers Lane  
Rockville MD 20857-0001

Management

Commissioner for Patents  
PO Box 1450  
Alexandria VA 22313-1450

Pazzallo, August 18, 2003

**Re: Application for Extension of Patent Term of US Patent No. 5,202,333  
"Tricyclic 5-HT<sub>3</sub> receptor antagonists"  
Roche Palo Alto LLC**


Gentlemen:

Helsinn Healthcare SA is the licensee of Roche Palo Alto LLC under US Patent No. 5,202,333 and the holder of Investigational New Drug exemption 39,797 (for palonosetron hydrochloride) and New Drug Application 21-372 (for Aloxi™ (palonosetron hydrochloride) injection).

Helsinn Healthcare SA hereby authorizes Roche Palo Alto LLC to rely upon the activities of Helsinn Healthcare SA before the US Food and Drug Administration during the regulatory review period in making its application for extension of the patent term of US Patent No. 5,202,333; and grants the Commissioner of Food and Drugs and the Commissioner for Patents the right to refer to the above IND and NDA in determining the eligibility of Roche Palo Alto LLC for such extension.

For and on behalf of

HELSINN HEALTHCARE SA



Dr. Riccardo Braglia  
Managing Director